ArticlePathogens and global health2017
Emergence of visceral leishmaniasis in Sri Lanka: a newly established health threat.
Article in Pathogens and global health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- An Insight Into Systemic Immune Response inFrontiers in immunology · 2021Trial
- Trend analysis and spatiotemporal distribution of leishmaniasis disease incidence in Sri Lanka: A detailed review from 2009 to 2023.PLoS neglected tropical diseases · 2025Review
- Article
- Autochthonous Leishmaniasis Caused by Leishmania tropica, Identified by Using Whole-Genome Sequencing, Sri Lanka.Emerging infectious diseases · 2024Article
- Cytokine and phenotypic cell profiles in human cutaneous leishmaniasis caused by Leishmania donovani.PloS one · 2023Article
- The immune response in canine and human leishmaniasis and how this influences the diagnosis- a review and assessment of recent research.Frontiers in cellular and infection microbiology · 2023Review
- Assessment of Risk of Exposure toPathogens (Basel, Switzerland) · 2022Article
- Development of Quantitative Rapid Isothermal Amplification Assay forDiagnostics (Basel, Switzerland) · 2021Article
- Detection ofJournal of tropical medicine · 2021Article
- First Evidence from Sri Lanka for Subphenotypic Diversity withinBioMed research international · 2021Article
- A Comprehensive Review of Cutaneous Leishmaniasis in Sri Lanka and Identification of Existing Knowledge Gaps.Acta parasitologica · 2020Review
- First Serological Study Revealing High Humoral Response and Evidence for Antigenic Heterogeneity inBioMed research international · 2020Article
- Spatial Epidemiologic Trends and Hotspots of Leishmaniasis, Sri Lanka, 2001-2018.Emerging infectious diseases · 2020Article
- Prevalidation of an ELISA for Detection of a New Clinical Entity:International journal of analytical chemistry · 2020Article
- Imported cutaneous leishmaniasis: molecular investigation unveils Leishmania major in Bangladesh.Parasites & vectors · 2019Article
- A highly sensitive modified nested PCR to enhance case detection in leishmaniasis.BMC infectious diseases · 2019Article
- First Evidence for Two Independent and Different Leishmaniasis Transmission Foci in Sri Lanka: Recent Introduction or Long-Term Existence?Journal of tropical medicine · 2019Article
- Article
- Trends in Recently EmergedBioMed research international · 2019Article
- Atypical leishmaniasis: A global perspective with emphasis on the Indian subcontinent.PLoS neglected tropical diseases · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSri Lanka is a new focus of human cutaneous leishmaniasis caused by a genetic variant of usually visceralizing parasite Leishmania donovani. Over 3000 cases have been reported to our institution alone, during the past two decades. Recent emergence of visceral leishmaniasis is of concern.
methodsPatients suspected of having visceral leishmaniasis (n = 120) fulfilling at least two of six criteria (fever > 2 weeks, weight loss, tiredness affecting daily functions, splenomegaly, hepatomegaly and anemia) were studied using clinic-epidemiological, immunological and haematological parameters. Seven cases (four progressive, treated (group A) and 3 non- progressive, potentially asymptomatic and observed (group B) were identified. Clinical cases were treated with systemic sodium stibogluconate or amphotericin B and all were followed up at the leishmaniasis clinic of University of Colombo for 3 years with one case followed up for 9 years.
resultsAll treated cases responded well to anti leishmanial treatment. Relapses were not noticed. Clinical features subsided in all non-progressive cases and did not develop suggestive clinical features or change of laboratory parameters. Visceral leishmaniasis cases have been originated from different districts within the country. Majority had a travel history to identified local foci of cutaneous leishmaniasis.
conclusionVisceral leishmaniasis is recognized as an emerging health threat in Sri Lanka. At least a proportion of locally identified strains of L. donovani possess the ability to visceralize. Apparent anti leishmanial sensitivity is encouraging. Timely efforts in disease containment will be important in which accurate understanding of transmission characteristics, increased professional and community awareness, improved diagnostics and availability of appropriate treatment regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.